Lore Gruenbaum tells us about her career spanning big pharma, biotech and now The Leukemia & Lymphoma Society.

Job cuts at the FDA spark concern, with Robert Califf saying the agency as we know it is “finished.”

Looking ahead to the next 5–10 years, what will be the key disruptors and/or what can be improved upon in the pharma industry?

Biotech Versus the Superbugs: Interviewing Centauri Therapeutics CSO Helen Bright

Celon Pharma CEO hopes their new compound could be a potential breakthrough for Parkinson’s patients.

We ask James Chambers from Tufts Medical Center about the challenges faced by biosimilars in the US.

We dive into the archive of 2021 for insight and inspiration – this time with Peter Marks

Some scientists believe “dark” regions could be the key to understanding the relationship between our genetic makeup and diseases.

Here’s how researchers took lessons from cephalopods to develop a new capsule that can deliver drugs, including insulin and siRNA, orally.

Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems; we ask experts about the future of advanced medicine.